Zoetis Inc. (NYSE:ZTS) Holdings Decreased by Yarbrough Capital LLC

Yarbrough Capital LLC lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 54.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,945 shares of the company's stock after selling 2,322 shares during the period. Yarbrough Capital LLC's holdings in Zoetis were worth $317,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Pensionfund Sabic lifted its position in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company's stock worth $1,825,000 after purchasing an additional 4,000 shares in the last quarter. PFW Advisors LLC bought a new position in shares of Zoetis during the 4th quarter worth approximately $1,764,000. JPMorgan Chase & Co. grew its stake in shares of Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company's stock valued at $569,834,000 after buying an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in shares of Zoetis in the third quarter valued at approximately $11,684,000. Finally, B&L Asset Management LLC acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $563,000. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ZTS. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Finally, UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $211.89.

Zoetis Stock Performance

NYSE ZTS traded down $3.21 on Friday, reaching $166.16. The stock had a trading volume of 1,928,159 shares, compared to its average volume of 2,611,749. The stock has a market cap of $74.97 billion, a P/E ratio of 31.23, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The business's 50-day moving average price is $171.25 and its 200 day moving average price is $180.07. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same quarter in the prior year, the firm posted $1.36 EPS. The company's revenue was up 11.6% compared to the same quarter last year. As a group, equities analysts expect that Zoetis Inc. will post 5.91 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis's previous quarterly dividend of $0.43. Zoetis's dividend payout ratio is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.